CA2144155A1 - Ibuprofen-h2 antagonist combinations - Google Patents
Ibuprofen-h2 antagonist combinationsInfo
- Publication number
- CA2144155A1 CA2144155A1 CA002144155A CA2144155A CA2144155A1 CA 2144155 A1 CA2144155 A1 CA 2144155A1 CA 002144155 A CA002144155 A CA 002144155A CA 2144155 A CA2144155 A CA 2144155A CA 2144155 A1 CA2144155 A1 CA 2144155A1
- Authority
- CA
- Canada
- Prior art keywords
- ibuprofen
- lysine
- salt
- famotidine
- analgesically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and in the relief of indigestion, sour stomach, heartburn and other gastrointestinal disorders in mammals, including humans, by administering compositions comprising (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; and (ii) an amount effec-tive in the relief of indigestion, sour stomach, heartburn, overindulgence and other gastrointestinal disorders of at least one of the H2 antagonists.
Description
2 1 4 ~ 1 5 5 PCI'/US93/08947 TITLE OF THE INV~ENTION
BACKGROUND OF THE INVENTION
The non-steroidal anti-infl~mm~tory drugs (NSAID) have been utilized in the treatment of pain/infl~mm~ion and a number of other symptoms including stiffness that are associated with painful conditions affecting muscles, bones, and joints. NSAIDs have been prescribed to relieve back pain, arthritic pain, gout, menstrual pain, headaches, mild pain following surgery, and pain from soft tissue injuries such as sprains and strains. NSAIDs are within the broader class of non-narcotic analgesics which also includes acetyl salicyclic acid (aspirin) and acetaminophen. NSAIDs, except for acetaminophen, are generally considered to exert their effect by blocking the production of prost~gl~ndins at the site of pain, irritation or injury so that the pain signal does not reach the brain.
Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID. Amino acid salts of racemic ibuprofen including the lysine or arginine salt are also known pain relievers. See U.S. Pat. No. 4,279,926. Recently, it has been found that a faster onset of pain relief and an enhanced analgesic response can be obtained by l~tili7ing the single enantiomer (S)-ibuprofen (also known as (+)-ibuprofen or dexil,uplofen) rather than the racemic mixture of ibuprofen. See U.S. Patent 4,877,620.
H2 antagonists are commonly prescribed to treat and prevent ulcers in the walls of the stomach, duodenum or esophagus. H2 antagonists are also used to treat non-ulcerative conditions. Damage to the mucus lining surrolln-ling these tissues enables destructive action of stomach acids which erodes the underlying tissue. Commonly known H2 antagonists for the treatment of ulcers include cimetidine, ranitidine, nizatidine, roxatidine and famotidine.
Combinations of ibuprofen with H2 antagonists have been disclosed. See EPO App. No. 426479A which discloses a pharmaceutical composition for treating the symptoms of WO 94/07541 PCI'/US93/08,9~
2 1 4.~
overindulgence (hP~ rhe and acid indigestion) using H2 antagonists including famotidine and an analgesic effective amount of a NSAID
including ibuprofen wherein the term is defined to include ~dmini~tration of both the racemic mixture or the pure S enantiomer of 5 ibuprofen. There is a need to employ a compound with faster acting and enhanced analgesic capability such as (i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen subst~nti~lly free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; in combination with an H2 o antagonist such as famotidine to treat and prevent the pain and discomfort associated with headaches, indigestion, sour stomach, heartburn or other gastrointestinal disorders. There is a need to employ a combination wherein an advantage is that the (S)-ibuprofen lysine salt is more stable than the free acid of ibul~rofen and is extremely soluble 15 in water to give subst~nti~lly neutral (versus acidic) aqueous solutions.
The ibuprofen/lysine salt is therefore more suitable for ~-lmini~tration to patients than the free acid because of its enhanced solubility in water (and in plasma) and because of its neutrality. Because of these improved and advantageous physical properties, ~clminictration of the 20 combination is more effective in the treatment of pain, infl~mm~tion, and overindulgence. In addition, an advantage of the (S)-ibuprofen-(S)-lysine in the combination claimed in the instant invention is that this salt is neutral and not acidic and, therefore, unlike the prior art disclosures of H2 antagonist and ibuprofen, does not both acerbate and 25 treat stomach conditions siml~lt~neously.
The present invention provides both faster onset and enhanced relief of aches and pains associated with the body, head and stomach to provide broad and con~;u"ellt symptomatic relief. The combination with famotidine is especially advantageous since (S)-30 ibuprofen-lysine does not interfere with the metabolism of famotidine nor does famotidine interfere wi~ the metabolism of alcohol.
` 2~15~ -DETAILED DESCRIPTION OF THE INVENTION
This invention claims pharmaceutical compositions for use in the treatment of pain and infl~mm~tion and the treatment of mild stomach and esophagus disorders including the treatment of heartburn.
5 The composition comprises:
(i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
This invention is also directed to a method of treating pain and iILfl~mm~tion and concurrently treating indigestion, sour stomach, 5 heartburn, overindulgence and other gastrointestinal disorders in m~mm~ls, including hllm~n~, in need thereof, comprising ~lmini.~tering to such org~nism:
(i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt 20 iS selected from (S)-ibul rofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
This invention is further directed to a method of eliciting 25 an onset hastened and enhanced response for the treatment of pain and infl~mm~tion and the treatment of gastrointestinal or esophagus disorders in m~mm~l.s, including hllm~n.s, in need thereof, comprising lmini.stering to such organism:
(i) an analgesically and anti-infl~mm~tory effective amount of a 30 salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt - is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
WO 94/07541 PCI/US93/0~
i ~ ~4~1 SS
Substantially free of (R)-ibuprofen means that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10.
Salts of (S)-ibuprofen include ph~rm~ceutically acceptable salts such as alkali metals (sodium or potassium), ~lk~line earth metals 5 (calcium), or salts with other metals such as m~gnesium, al1-minllm, iron, zinc, copper, nickel or cobalt.
Pharmaceutically acceptable salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the composition of the o instant invention is (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine.
The term m~mm~l~ or m~mm~ n organism includes but is not limited to man, dog, cat, horse and cow.
The term treatment encompasses the complete range of 15 therapeutically positive effects associated with pharmaceutical medication including reduction of, alleviation of and relief from the symptoms or illness which affect the org~ni~m (S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620. Metal salts of ibuprofen may be 20 obtained by contacting a hydroxide, or carbonate with ibuprofen.
Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen. U.S. Patent No. 4,994,604 describes a process for the formation and resolution of (S)-ibuprofen-(S)-lysine that employs preferential cryst~lli7~tion to separate a pair of diastereomeric 25 salts, (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. The basic procedure involves (a) contacting (R),(S)-ibuprofen and (S)-lysine in an aqueous-organic solvent mixture; (b) separating any suspended solid from the mixture; and (c) cooling the clear mixture until the mixture is supersaturated with respect to each of the (S)-ibuprofen-(S)-lysine and 30 (R)-ibuprofen-(S)-lysine salts; (d) contacting the supersaturated mixture with a slurry of (S)-ibuprofen-(S)-lysine in an aqueous-organic solvent;
and (e) separating the formed crystalline (S)-ibuprofen-(S)-lysine.
Specifically, the racemic ibuprofen starting material is mixed with an organic solvent that is miscible with water. The (S)-WO 94/07541 PCl/US93/08947 `: 2144155 lysine is mixed with water and the ibuprofen and lysine solutions arecombined.
The mixture is agitated for a time period sufficient to crystallize all the salts, if any, in excess of the solubility limit. The 5 suspended salts are separated to obtain a clear mother liquor which is generally saturated with respect to the diastereomeric salts (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. Filtration may be employed to effect the separation. The liquor is then cooled to a temperature at which it is supersaturated with respect to each of the o diastereomeric salts. It is preferred that the liquor be cooled to the point at which maximllm supersaturation is obtained with respect to each salt without nucleation of either cryst~lli7~ble species. Typically the temperature of the mother liquor must be lowered by about 5C to reach maximl1m supersaturation without precipitation of either salt.
5 However, the degree of cooling will depend on the particular solvent composition. The supersaturated liquor is then passed into a vessel cont~ining a slurry of (S)-ibuprofen-(S)-lysine, hereafter referred to as the (S,S) salt, in the same solvent system employed above for the n~ e of racemic ibuprofen and (S)-lysine. In the presence of the 20 (S,S) salt crystals acting as a seed, the supersaturation of the (S,S)-salt in the feed liquor is released by the growth of further crystals of the (S,S)-salt. Conversely, there is little or no change in the (R)-ibuprofen-(S)-lysine supersaturation because the growth rate of the (R,S) crystals is essentially zero in the absence of any initial (R,S) salt seed. The (S,S) 25 crystals are then separated by filtration or centrii~ugation and washed with aqueous-organic solvent to yield (S)-ibuprofen-(S)-lysine of purity approxim~ting 98%.
The pharmaceutical compositions of the present invention are useful in the rapid and enhanced treatment of pain and infl~mm~tion 3~ and in the treatment of various mild gastrointestinal disorders including indigestion, sour stomach, overindulgence and heartburn. In particular, the (S)-ibuprofen-(S)-lysine combined with an H2 antagonist such as famotidine is useful for the treatment of pain, infl~mm~tion, and the various gastrointestinal disorders such as indigestion, sour stomach, or WO 94/07541 ? ~4 4~S~ PCI/US93/0*
~; ~ f ~, ~
heartburn. The l-tili7~tion of (S)-ibuprofen and in particular (S)-ibuprofen-(S)-lysine in an analgesic/H2 antagonist combination offers significant advantages over the combination of racemic ibuprofen and an H2 antagonist or (S)-ibuprofen and an H2 antagonist.
(S)-ibuprofen and in particular the (S)-lysine salt of (S)-ibuprofen provides a faster onset of pain and infl~mm~tion relief and an eIlh~nced degree of relief compared to racemic ibuprofen. These benefits contribute to overall enhanced and faster relief of symptoms associated with headaches and other aches and pains that often o accompany gastrointestinal disorders and overindulgence when the (S)-ibuprofen-(S)-lysine is combined with an H2 antagonist such as famotidine.
The absence or reduction of (R)-ibuprofen also provides significant benefits. The allergic contraindications sometimes associated 15 with ibu~rofen ~lmini,stration are absent or reduced in a (R)-ibuprofen-free or subst~nti~lly-free composition. An additional advantage may be that less metabolic energy will be used to convert the inactive (R)-ibuprofen to the active (S)-ibuprofen. In addition, a reduced burden may be placed on the urogenital system since ~lministration of the pure 20 (S)-ibuprofen elimin~tes the need to excrete the (R)-ibuprofen or its metabolites. The absence of the (R)-enantiomer also reduces or elimin~tes the incorporation of this molecule into fatty tissue. The renal burden and renal toxicities sometimes associated with racemic il~u~rofen therapy may be reduced or elimin~ted in a (S)-ibuprofen composition 25 that is subst~nti~lly free of the (R) enantiomer.
H2 antagonists are well known in the treatment of ulcers and other gastrointestinal disorders and may be used in combination with (S)-ibuprofen-(S)-lysine. H2 antagonists used for ulcer therapy fall into four major structural classes: imidazole derivatives; substituted 30 furans; aminoalkylphenoxy derivatives and guanidinothiazole compounds. Famotidine (N'-(aminosulfonyl)-3-[[[2-[(cli~mino-methylene)amino]-4-thiazolyl]methyl]thio] propanimidamide), a member of the latter class, is a competitive inhibitor of histamine H2-receptors and its primary pharmacological activity is the inhibition of ~ WO 94/07541 PCI'/US93/08947 , ! ' ~ j 21~155 gastric acid secretion. Famotidine suppresses both the acid concentration and the volume of gastric acid secretion. Famotidine is well tolerated and has minim~l side effects and thus advantageously may be used in the present invention in combination with (S)-ibuprofen-(S)-5 lysine. Famotidine is also the most potent and selective H2 antagonist.The combination of famotidine and (S)-ibù~rofell-(S)-lysine provides a combination which simlllt~neously and selectively provides relief from headaches, pain, infl~mm~tion, and discomfort and injury to the stomach, esophagus, or duodenum from excess production of gastric o acid. Furthermore, famotidine may not interact with alcohol so that it may be ~clminictered prior to or during ingestion of meals or beverages which contain alcohol. The combination of (S)-ibuprofen-(S)-lysine with famotidine provides rapid and enhanced relief of pain while also providing long acting relief from and treatment of gastrointestinal 15 disorders associated with gastric acid secretion.
The absence of inactive enantiomers, particularly (R)-ibu~rofell provides for significant size and weight advantages in a combination dosage form, particularly a sustained release dosage form.
Where a sustained release dosage of ibuprofen may have required 800 20 to 1000 mg, the employment of (S)-ibuprofen-(S)-lysine reduces the weight to 400 to 500 mg, and provides for a more practical size tablet for an ibuprofen/H2 antagonist combination. In particular, the combination of famotidine which is a highly potent H2 antagonist with (S)-ibuprofen-(S)-lysine reduces the size and weight of all 25 pharmaceutical delivery forms or combination form~ tions and therefore improves patient compliance or tolerance. The tablet or capsule form of this combination is more readily swallowable by patients in need of treatment thereof.
An effective amount of (S)-ibuprofen, or a salt thereof, for 30 use in a unit dose composition of this invention may range from 50-800 mg of (S)-ibuprofen equivalents. The preferred amount of (S)-ibuprofen is about 100 to 400 mg. The amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
WO 94/07541 PCI`/US93/0 S~
The H2 antagonist employed herein may be selected from any of the commercially available or known H2 antagonists such as cimetidine, ranitidine, roxatidine, nizatidine or famotidine. Famotidine is advantageously used in the present invention in combination with (S)-5 ibuprofen-(S)-lysine. The amount of famotidine used in the present invention in hl-m~n~ may range from 2.5 mg/day to 40 mg/day.
Advantageously, 2.5 to 20 mgs/day is ~rlminictered in combination with 100 to 400 mg of (S)-ibuprofen-(S)-lysine. The combination claimed in the instant invention is advantageously ~lmini.~tered orally. However, o in patients with hypersecretory conditions, intractable ulcers, or in patients who are unable to take oral medication, the claimed combination may be ~lmini~tered intravenously in a suitable dosage within the limits described for oral treatment.
The present composition may be ~flmini~tered in the form 15 of tablets, caplets, gelcaps, capsules, elixirs, syrups, or suspensions. For oral ~lmini~tration~ the active ingredients may be admixed with a pharmaceutically acceptable diluent such as lactose, sucrose, cellulose, dicalcium phosphate, calcium sulfate, m~nnitol, and, in a liquid composition, ethyl alcohol. Acceptable emulsifying or suspending agents such as PVP, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, guar gum, agar, bentonite, carboxymethylcellulose sodium, polyethylene glycol and waxes, may also be admixed with the active components. Where necessary, lubricants such as m~nesium stearic acid talc or m~gnesium stearate, and disintegrators or superdisintegrators such as starch, sodium starch glycolate or cross-linked PVP may also be included.
Electrolytes such as dicalcium phosphate, sodium benzoate, sodium acetate and sodium chloride may also be used.
The active components may also be formulated in sustained release oreffervescentform~ tions. These formulations depending upon whether they are sustained release or effervescent may be employed in oral, dermal, rectal or vaginal ~lmini~trations. The sustained release formulations also include layered formulations which 2 ~ S
provide for distinct release ratio and thus may be more effective in allowing for short and long term relief.
The following examples illustrate ~e compositions of the present invention which may be readily prepared and as such are not to be considered as limiting the invention set forth in the claims.
(S)-Ibuprofen Iysine/famotidine Tablet (S)-ibuprofen-(S)-lysine342 mg famotidine 40 mg PVP 15 mg Avicel PH101 40 mg 15 Magnesium Stearate4 mg (S)-Ibuprofen lysine/famotidine Tablet (S)-ibuprofen-(S)-lysine342 mg famotidine 20 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate4 mg -WO 94/07541 PCr/US93/0 (S)-Ibuprofen Iysine/famotidine Tablet 5 (S)-ibuprofen-(S)-lysine 342 mg famotidine 15 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg (S)-Ibuprofen Iysine/famotidine Tablet 15 (S)-ibuprofen-(S)-lysine 342 mg famotidine 10 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg (S)-Ibuprofen Iysine/famotidine Tablet 25 (S)-ibuprofen-(S)-lysine 342 mg famotidine 5 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg PCI~/US93/08947 2i4~ls5 (S)-Ibuprofen Iysine/famotidine Sustained Release (S)-ibuprofen-(S)-lysine400 mg famotidine 40 mg PVP 30 mg Avicel PH101 80 mg Magnesium Stearate 8 mg o Methocel ElOMCR 66 mg Methocel KlOOMLV 200 mg (S)-Ibuprofen (S)-lysine/famotidine Sustained Release (S)-ibuprofen-(S)-lysine 400 mg famotidine 20 mg PVP 30 mg Avicel PH101 80 mg Magnesium Stearate 8 mg Methocel ElOMCR 66 mg Methocel KlOOMLV 200 mg (S)-Ibuprofen-(S)-lysine/famotidine Solution (S)-ibuprofen-(S)-lysine 342 mg famotidine 10 mg g.s. syrup 5 ml WO 94/07541 PCI'/US93/0~
2l4~l~3 (S)-Ibuprofen-(S)-lysine/farnotidine Solution 5 (S)-ibuprofen-(S)-lysine 342 mg famotidine 20 mg g.s. syrup 5 ml
BACKGROUND OF THE INVENTION
The non-steroidal anti-infl~mm~tory drugs (NSAID) have been utilized in the treatment of pain/infl~mm~ion and a number of other symptoms including stiffness that are associated with painful conditions affecting muscles, bones, and joints. NSAIDs have been prescribed to relieve back pain, arthritic pain, gout, menstrual pain, headaches, mild pain following surgery, and pain from soft tissue injuries such as sprains and strains. NSAIDs are within the broader class of non-narcotic analgesics which also includes acetyl salicyclic acid (aspirin) and acetaminophen. NSAIDs, except for acetaminophen, are generally considered to exert their effect by blocking the production of prost~gl~ndins at the site of pain, irritation or injury so that the pain signal does not reach the brain.
Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID. Amino acid salts of racemic ibuprofen including the lysine or arginine salt are also known pain relievers. See U.S. Pat. No. 4,279,926. Recently, it has been found that a faster onset of pain relief and an enhanced analgesic response can be obtained by l~tili7ing the single enantiomer (S)-ibuprofen (also known as (+)-ibuprofen or dexil,uplofen) rather than the racemic mixture of ibuprofen. See U.S. Patent 4,877,620.
H2 antagonists are commonly prescribed to treat and prevent ulcers in the walls of the stomach, duodenum or esophagus. H2 antagonists are also used to treat non-ulcerative conditions. Damage to the mucus lining surrolln-ling these tissues enables destructive action of stomach acids which erodes the underlying tissue. Commonly known H2 antagonists for the treatment of ulcers include cimetidine, ranitidine, nizatidine, roxatidine and famotidine.
Combinations of ibuprofen with H2 antagonists have been disclosed. See EPO App. No. 426479A which discloses a pharmaceutical composition for treating the symptoms of WO 94/07541 PCI'/US93/08,9~
2 1 4.~
overindulgence (hP~ rhe and acid indigestion) using H2 antagonists including famotidine and an analgesic effective amount of a NSAID
including ibuprofen wherein the term is defined to include ~dmini~tration of both the racemic mixture or the pure S enantiomer of 5 ibuprofen. There is a need to employ a compound with faster acting and enhanced analgesic capability such as (i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen subst~nti~lly free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; in combination with an H2 o antagonist such as famotidine to treat and prevent the pain and discomfort associated with headaches, indigestion, sour stomach, heartburn or other gastrointestinal disorders. There is a need to employ a combination wherein an advantage is that the (S)-ibuprofen lysine salt is more stable than the free acid of ibul~rofen and is extremely soluble 15 in water to give subst~nti~lly neutral (versus acidic) aqueous solutions.
The ibuprofen/lysine salt is therefore more suitable for ~-lmini~tration to patients than the free acid because of its enhanced solubility in water (and in plasma) and because of its neutrality. Because of these improved and advantageous physical properties, ~clminictration of the 20 combination is more effective in the treatment of pain, infl~mm~tion, and overindulgence. In addition, an advantage of the (S)-ibuprofen-(S)-lysine in the combination claimed in the instant invention is that this salt is neutral and not acidic and, therefore, unlike the prior art disclosures of H2 antagonist and ibuprofen, does not both acerbate and 25 treat stomach conditions siml~lt~neously.
The present invention provides both faster onset and enhanced relief of aches and pains associated with the body, head and stomach to provide broad and con~;u"ellt symptomatic relief. The combination with famotidine is especially advantageous since (S)-30 ibuprofen-lysine does not interfere with the metabolism of famotidine nor does famotidine interfere wi~ the metabolism of alcohol.
` 2~15~ -DETAILED DESCRIPTION OF THE INVENTION
This invention claims pharmaceutical compositions for use in the treatment of pain and infl~mm~tion and the treatment of mild stomach and esophagus disorders including the treatment of heartburn.
5 The composition comprises:
(i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
This invention is also directed to a method of treating pain and iILfl~mm~tion and concurrently treating indigestion, sour stomach, 5 heartburn, overindulgence and other gastrointestinal disorders in m~mm~ls, including hllm~n~, in need thereof, comprising ~lmini.~tering to such org~nism:
(i) an analgesically and anti-infl~mm~tory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt 20 iS selected from (S)-ibul rofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
This invention is further directed to a method of eliciting 25 an onset hastened and enhanced response for the treatment of pain and infl~mm~tion and the treatment of gastrointestinal or esophagus disorders in m~mm~l.s, including hllm~n.s, in need thereof, comprising lmini.stering to such organism:
(i) an analgesically and anti-infl~mm~tory effective amount of a 30 salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt - is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in relief of gastrointestinal or esophagus disorders of at least one of the H2 antagonists.
WO 94/07541 PCI/US93/0~
i ~ ~4~1 SS
Substantially free of (R)-ibuprofen means that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10.
Salts of (S)-ibuprofen include ph~rm~ceutically acceptable salts such as alkali metals (sodium or potassium), ~lk~line earth metals 5 (calcium), or salts with other metals such as m~gnesium, al1-minllm, iron, zinc, copper, nickel or cobalt.
Pharmaceutically acceptable salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the composition of the o instant invention is (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine.
The term m~mm~l~ or m~mm~ n organism includes but is not limited to man, dog, cat, horse and cow.
The term treatment encompasses the complete range of 15 therapeutically positive effects associated with pharmaceutical medication including reduction of, alleviation of and relief from the symptoms or illness which affect the org~ni~m (S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620. Metal salts of ibuprofen may be 20 obtained by contacting a hydroxide, or carbonate with ibuprofen.
Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen. U.S. Patent No. 4,994,604 describes a process for the formation and resolution of (S)-ibuprofen-(S)-lysine that employs preferential cryst~lli7~tion to separate a pair of diastereomeric 25 salts, (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. The basic procedure involves (a) contacting (R),(S)-ibuprofen and (S)-lysine in an aqueous-organic solvent mixture; (b) separating any suspended solid from the mixture; and (c) cooling the clear mixture until the mixture is supersaturated with respect to each of the (S)-ibuprofen-(S)-lysine and 30 (R)-ibuprofen-(S)-lysine salts; (d) contacting the supersaturated mixture with a slurry of (S)-ibuprofen-(S)-lysine in an aqueous-organic solvent;
and (e) separating the formed crystalline (S)-ibuprofen-(S)-lysine.
Specifically, the racemic ibuprofen starting material is mixed with an organic solvent that is miscible with water. The (S)-WO 94/07541 PCl/US93/08947 `: 2144155 lysine is mixed with water and the ibuprofen and lysine solutions arecombined.
The mixture is agitated for a time period sufficient to crystallize all the salts, if any, in excess of the solubility limit. The 5 suspended salts are separated to obtain a clear mother liquor which is generally saturated with respect to the diastereomeric salts (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. Filtration may be employed to effect the separation. The liquor is then cooled to a temperature at which it is supersaturated with respect to each of the o diastereomeric salts. It is preferred that the liquor be cooled to the point at which maximllm supersaturation is obtained with respect to each salt without nucleation of either cryst~lli7~ble species. Typically the temperature of the mother liquor must be lowered by about 5C to reach maximl1m supersaturation without precipitation of either salt.
5 However, the degree of cooling will depend on the particular solvent composition. The supersaturated liquor is then passed into a vessel cont~ining a slurry of (S)-ibuprofen-(S)-lysine, hereafter referred to as the (S,S) salt, in the same solvent system employed above for the n~ e of racemic ibuprofen and (S)-lysine. In the presence of the 20 (S,S) salt crystals acting as a seed, the supersaturation of the (S,S)-salt in the feed liquor is released by the growth of further crystals of the (S,S)-salt. Conversely, there is little or no change in the (R)-ibuprofen-(S)-lysine supersaturation because the growth rate of the (R,S) crystals is essentially zero in the absence of any initial (R,S) salt seed. The (S,S) 25 crystals are then separated by filtration or centrii~ugation and washed with aqueous-organic solvent to yield (S)-ibuprofen-(S)-lysine of purity approxim~ting 98%.
The pharmaceutical compositions of the present invention are useful in the rapid and enhanced treatment of pain and infl~mm~tion 3~ and in the treatment of various mild gastrointestinal disorders including indigestion, sour stomach, overindulgence and heartburn. In particular, the (S)-ibuprofen-(S)-lysine combined with an H2 antagonist such as famotidine is useful for the treatment of pain, infl~mm~tion, and the various gastrointestinal disorders such as indigestion, sour stomach, or WO 94/07541 ? ~4 4~S~ PCI/US93/0*
~; ~ f ~, ~
heartburn. The l-tili7~tion of (S)-ibuprofen and in particular (S)-ibuprofen-(S)-lysine in an analgesic/H2 antagonist combination offers significant advantages over the combination of racemic ibuprofen and an H2 antagonist or (S)-ibuprofen and an H2 antagonist.
(S)-ibuprofen and in particular the (S)-lysine salt of (S)-ibuprofen provides a faster onset of pain and infl~mm~tion relief and an eIlh~nced degree of relief compared to racemic ibuprofen. These benefits contribute to overall enhanced and faster relief of symptoms associated with headaches and other aches and pains that often o accompany gastrointestinal disorders and overindulgence when the (S)-ibuprofen-(S)-lysine is combined with an H2 antagonist such as famotidine.
The absence or reduction of (R)-ibuprofen also provides significant benefits. The allergic contraindications sometimes associated 15 with ibu~rofen ~lmini,stration are absent or reduced in a (R)-ibuprofen-free or subst~nti~lly-free composition. An additional advantage may be that less metabolic energy will be used to convert the inactive (R)-ibuprofen to the active (S)-ibuprofen. In addition, a reduced burden may be placed on the urogenital system since ~lministration of the pure 20 (S)-ibuprofen elimin~tes the need to excrete the (R)-ibuprofen or its metabolites. The absence of the (R)-enantiomer also reduces or elimin~tes the incorporation of this molecule into fatty tissue. The renal burden and renal toxicities sometimes associated with racemic il~u~rofen therapy may be reduced or elimin~ted in a (S)-ibuprofen composition 25 that is subst~nti~lly free of the (R) enantiomer.
H2 antagonists are well known in the treatment of ulcers and other gastrointestinal disorders and may be used in combination with (S)-ibuprofen-(S)-lysine. H2 antagonists used for ulcer therapy fall into four major structural classes: imidazole derivatives; substituted 30 furans; aminoalkylphenoxy derivatives and guanidinothiazole compounds. Famotidine (N'-(aminosulfonyl)-3-[[[2-[(cli~mino-methylene)amino]-4-thiazolyl]methyl]thio] propanimidamide), a member of the latter class, is a competitive inhibitor of histamine H2-receptors and its primary pharmacological activity is the inhibition of ~ WO 94/07541 PCI'/US93/08947 , ! ' ~ j 21~155 gastric acid secretion. Famotidine suppresses both the acid concentration and the volume of gastric acid secretion. Famotidine is well tolerated and has minim~l side effects and thus advantageously may be used in the present invention in combination with (S)-ibuprofen-(S)-5 lysine. Famotidine is also the most potent and selective H2 antagonist.The combination of famotidine and (S)-ibù~rofell-(S)-lysine provides a combination which simlllt~neously and selectively provides relief from headaches, pain, infl~mm~tion, and discomfort and injury to the stomach, esophagus, or duodenum from excess production of gastric o acid. Furthermore, famotidine may not interact with alcohol so that it may be ~clminictered prior to or during ingestion of meals or beverages which contain alcohol. The combination of (S)-ibuprofen-(S)-lysine with famotidine provides rapid and enhanced relief of pain while also providing long acting relief from and treatment of gastrointestinal 15 disorders associated with gastric acid secretion.
The absence of inactive enantiomers, particularly (R)-ibu~rofell provides for significant size and weight advantages in a combination dosage form, particularly a sustained release dosage form.
Where a sustained release dosage of ibuprofen may have required 800 20 to 1000 mg, the employment of (S)-ibuprofen-(S)-lysine reduces the weight to 400 to 500 mg, and provides for a more practical size tablet for an ibuprofen/H2 antagonist combination. In particular, the combination of famotidine which is a highly potent H2 antagonist with (S)-ibuprofen-(S)-lysine reduces the size and weight of all 25 pharmaceutical delivery forms or combination form~ tions and therefore improves patient compliance or tolerance. The tablet or capsule form of this combination is more readily swallowable by patients in need of treatment thereof.
An effective amount of (S)-ibuprofen, or a salt thereof, for 30 use in a unit dose composition of this invention may range from 50-800 mg of (S)-ibuprofen equivalents. The preferred amount of (S)-ibuprofen is about 100 to 400 mg. The amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
WO 94/07541 PCI`/US93/0 S~
The H2 antagonist employed herein may be selected from any of the commercially available or known H2 antagonists such as cimetidine, ranitidine, roxatidine, nizatidine or famotidine. Famotidine is advantageously used in the present invention in combination with (S)-5 ibuprofen-(S)-lysine. The amount of famotidine used in the present invention in hl-m~n~ may range from 2.5 mg/day to 40 mg/day.
Advantageously, 2.5 to 20 mgs/day is ~rlminictered in combination with 100 to 400 mg of (S)-ibuprofen-(S)-lysine. The combination claimed in the instant invention is advantageously ~lmini.~tered orally. However, o in patients with hypersecretory conditions, intractable ulcers, or in patients who are unable to take oral medication, the claimed combination may be ~lmini~tered intravenously in a suitable dosage within the limits described for oral treatment.
The present composition may be ~flmini~tered in the form 15 of tablets, caplets, gelcaps, capsules, elixirs, syrups, or suspensions. For oral ~lmini~tration~ the active ingredients may be admixed with a pharmaceutically acceptable diluent such as lactose, sucrose, cellulose, dicalcium phosphate, calcium sulfate, m~nnitol, and, in a liquid composition, ethyl alcohol. Acceptable emulsifying or suspending agents such as PVP, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, guar gum, agar, bentonite, carboxymethylcellulose sodium, polyethylene glycol and waxes, may also be admixed with the active components. Where necessary, lubricants such as m~nesium stearic acid talc or m~gnesium stearate, and disintegrators or superdisintegrators such as starch, sodium starch glycolate or cross-linked PVP may also be included.
Electrolytes such as dicalcium phosphate, sodium benzoate, sodium acetate and sodium chloride may also be used.
The active components may also be formulated in sustained release oreffervescentform~ tions. These formulations depending upon whether they are sustained release or effervescent may be employed in oral, dermal, rectal or vaginal ~lmini~trations. The sustained release formulations also include layered formulations which 2 ~ S
provide for distinct release ratio and thus may be more effective in allowing for short and long term relief.
The following examples illustrate ~e compositions of the present invention which may be readily prepared and as such are not to be considered as limiting the invention set forth in the claims.
(S)-Ibuprofen Iysine/famotidine Tablet (S)-ibuprofen-(S)-lysine342 mg famotidine 40 mg PVP 15 mg Avicel PH101 40 mg 15 Magnesium Stearate4 mg (S)-Ibuprofen lysine/famotidine Tablet (S)-ibuprofen-(S)-lysine342 mg famotidine 20 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate4 mg -WO 94/07541 PCr/US93/0 (S)-Ibuprofen Iysine/famotidine Tablet 5 (S)-ibuprofen-(S)-lysine 342 mg famotidine 15 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg (S)-Ibuprofen Iysine/famotidine Tablet 15 (S)-ibuprofen-(S)-lysine 342 mg famotidine 10 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg (S)-Ibuprofen Iysine/famotidine Tablet 25 (S)-ibuprofen-(S)-lysine 342 mg famotidine 5 mg PVP 15 mg Avicel PH101 40 mg Magnesium Stearate 4 mg PCI~/US93/08947 2i4~ls5 (S)-Ibuprofen Iysine/famotidine Sustained Release (S)-ibuprofen-(S)-lysine400 mg famotidine 40 mg PVP 30 mg Avicel PH101 80 mg Magnesium Stearate 8 mg o Methocel ElOMCR 66 mg Methocel KlOOMLV 200 mg (S)-Ibuprofen (S)-lysine/famotidine Sustained Release (S)-ibuprofen-(S)-lysine 400 mg famotidine 20 mg PVP 30 mg Avicel PH101 80 mg Magnesium Stearate 8 mg Methocel ElOMCR 66 mg Methocel KlOOMLV 200 mg (S)-Ibuprofen-(S)-lysine/famotidine Solution (S)-ibuprofen-(S)-lysine 342 mg famotidine 10 mg g.s. syrup 5 ml WO 94/07541 PCI'/US93/0~
2l4~l~3 (S)-Ibuprofen-(S)-lysine/farnotidine Solution 5 (S)-ibuprofen-(S)-lysine 342 mg famotidine 20 mg g.s. syrup 5 ml
Claims (18)
1. A pharmaceutical composition for use in the treatment of pain and inflammation and the treatment of gastrointestinal disorders such as indigestion, sour stomach, overindulgence and heartburn in a mammals, including humans comprising:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the relief of gastrointestinal disorders and in inhibition of gastric acid secretion of an H2 receptor antagonist.
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the relief of gastrointestinal disorders and in inhibition of gastric acid secretion of an H2 receptor antagonist.
2. The composition of Claim 1 wherein the ibuprofen is present as (S)-ibuprofen-(S)-lysine.
3. The composition of Claim 1 comprising at least 50 mg of (S)-ibuprofen-(S)-lysine.
4. The composition of Claim 1 wherein the H2 antagonist is selected from: cimetidine, ranitidine, roxatidine, nizatidine or famotidine or a pharmaceutically acceptable salt thereof.
5. The composition of claim 4 wherein the H2 antagonist is famotidine.
6. The composition of claim 5 comprising between 5 mg to 40 mgs of famotidine.
7. A method of treating pain and inflammation and treating gastrointestinal disorders such as indigestion, sour stomach, overindulgence and heartburn in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the treatment of gastrointestinal disorders or associated symptoms of at least one of the H2 antagonists.
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the treatment of gastrointestinal disorders or associated symptoms of at least one of the H2 antagonists.
8. A method according to Claim 7 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
9. A method of eliciting an onset enhanced and hastened response for the treatment and prevention of pain and inflammation and the treatment of gastrointestinal disorders such as indigestion, sour stomach, symptoms associated with overindulgence and heartburn in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the treatment of gastrointestinal disorders or associated symptoms of at least one of the H2 antagonists.
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine;
and (ii) an amount effective in the treatment of gastrointestinal disorders or associated symptoms of at least one of the H2 antagonists.
10. A method according to claim 9 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
11. A method of reducing the side effects associated with the administration of an ibuprofen/H2 antagonist combination which comprises the administration of (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; and at least one of the H2 antagonists.
12. A method according to Claim 11 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
13. A method of reducing the size and weight of a pharmaceutically effective amount of an ibuprofen/H2 antagonist combination dosage form which comprises combining (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; and at least one of the H2 antagonists.
14. A method according to Claim 13 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine, (ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine, (ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
15. A method of treating gastrointestinal disorders, overindulgence and pain before or during ingestion of a meal accompanied by alcoholic beverages, comprising:
administration of a combination of (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine and (ii) famotidine wherein the famotidine does not interact with ethanol from the ingestion of the alcoholic beverage.
administration of a combination of (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine and (ii) famotidine wherein the famotidine does not interact with ethanol from the ingestion of the alcoholic beverage.
16. A method according to Claim 15 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
17. A method of providing rapid relief of pain and inflammation with (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; and providing long lasting relief of gastrointestinal disorders associated with the secretion of gastric acid with a pharmaceutically effective amount of famotidine.
18. A method according to Claim 17 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine;
(ii) an amount effective in the inhibition of gastric acid secretion of famotidine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95344092A | 1992-09-29 | 1992-09-29 | |
| US953,440 | 1992-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2144155A1 true CA2144155A1 (en) | 1994-04-14 |
Family
ID=25493996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002144155A Abandoned CA2144155A1 (en) | 1992-09-29 | 1993-09-21 | Ibuprofen-h2 antagonist combinations |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0663839A4 (en) |
| JP (1) | JPH08502254A (en) |
| AU (1) | AU4931693A (en) |
| CA (1) | CA2144155A1 (en) |
| MX (1) | MX9306006A (en) |
| WO (1) | WO1994007541A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000028988A1 (en) | 1998-11-17 | 2000-05-25 | Nitromed, Inc. | Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US6926907B2 (en) | 2001-06-01 | 2005-08-09 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| SE0102993D0 (en) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| NZ565846A (en) * | 2005-07-18 | 2011-12-22 | Horizon Therapeutics Inc | Medicaments containing famotidine and ibuprofen and administration of same |
| US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| CA2657928C (en) * | 2006-07-18 | 2014-12-02 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| ES2590604T3 (en) | 2008-01-04 | 2016-11-22 | Schabar Research Associates Llc | Composition comprising an analgesic and an antihistamine |
| US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
| EA201290026A1 (en) | 2009-06-25 | 2012-07-30 | Астразенека Аб | A METHOD FOR TREATING A PATIENT THAT HAS A RISK OF DEVELOPMENT OF ANALISM ASSOCIATED WITH THE RECEPTION OF NONSTEROID ANTI-INFLAMMATORY MEDIA |
| UA115139C2 (en) | 2011-12-28 | 2017-09-25 | Поузен Інк. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| WO2015163832A1 (en) * | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
| CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| KR20230051164A (en) | 2020-07-15 | 2023-04-17 | 샤바르 리서치 어소시에이츠 엘엘씨 | Oral unit dosage composition consisting of ibuprofen and famotidine for treatment of acute pain and reduction of severity and/or risk of heartburn |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2105193B (en) * | 1981-09-04 | 1984-09-12 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| IN171746B (en) * | 1989-11-02 | 1992-12-26 | Mcneil Ppc Inc | |
| US4994604A (en) * | 1990-01-10 | 1991-02-19 | Merck & Co., Inc. | Formation and resolution of ibuprofen lysinate |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
-
1993
- 1993-09-21 EP EP93921709A patent/EP0663839A4/en not_active Withdrawn
- 1993-09-21 WO PCT/US1993/008947 patent/WO1994007541A1/en not_active Application Discontinuation
- 1993-09-21 JP JP6509138A patent/JPH08502254A/en active Pending
- 1993-09-21 CA CA002144155A patent/CA2144155A1/en not_active Abandoned
- 1993-09-21 AU AU49316/93A patent/AU4931693A/en not_active Abandoned
- 1993-09-28 MX MX9306006A patent/MX9306006A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4931693A (en) | 1994-04-26 |
| WO1994007541A1 (en) | 1994-04-14 |
| MX9306006A (en) | 1995-01-31 |
| JPH08502254A (en) | 1996-03-12 |
| EP0663839A4 (en) | 1998-06-03 |
| EP0663839A1 (en) | 1995-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2144155A1 (en) | Ibuprofen-h2 antagonist combinations | |
| US4571400A (en) | Dihydrocodeine/ibuprofen pharmaceutical compositions and method | |
| HU225887B1 (en) | Process for producing pharmaceutical compositions containing flurbiprofen having painkiller activity | |
| US4587252A (en) | Hydrocodone/ibuprofen pharmaceutical compositions and method | |
| EP0259990A1 (en) | Rapid acting combination of sodium sulindac and a base | |
| JPH08505133A (en) | Antipyretic and analgesic methods and compositions containing optically pure R-ketorolac | |
| JPH03206064A (en) | S(plus)-ibuprofen-l-amino acid and s(plus)- ibuprofen-d-amino acid as a pain-killing agent for producing an immediate and augmented analgesic efficacy | |
| US5288507A (en) | Ibuprofen antacid combinations | |
| AU642309B2 (en) | Complexes containing S(+) phenyl alkane acids and amino sugars | |
| WO1994003209A1 (en) | Dexibuprofen/antacid/simethicone combinations | |
| EP0707484A1 (en) | H 2? antagonist-alginate-antacid combinations | |
| US20170319519A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| CA2144152A1 (en) | Ibuprofen-caffine combinations | |
| WO1995001780A1 (en) | H2 antagonist-alginate combinations | |
| US4970202A (en) | Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs | |
| EP0551180B1 (en) | Use of bucillamine for the manufacture of a medicament for the treatment of cystinuria | |
| CA1124648A (en) | Anti-inflammatory combination having reduced ulcerogenicity | |
| WO1995001792A1 (en) | H2 antagonist-antihistamine combinations | |
| JP2000026313A (en) | Suppressant for enterokinesis | |
| AU695642B2 (en) | A novel antispasmodic and antinflammatory composition and a process for the manufacture thereof | |
| JP2004002454A (en) | Enterokinesis inhibitor | |
| CA2684171C (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas | |
| EP0868915A1 (en) | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium | |
| WO1995001784A1 (en) | H2 antagonist-sucralfate-antiflatulent combinations | |
| CA1227136A (en) | Pharmaceutical compositions containing 4-(benzofuran- 2-yl)4-oxo buten-2-oic acid and/or one of the pharmaceutically acceptable salts thereof as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |